← All companies ← CAH Manual CAKE → ← BRKRP Life Sciences Tools & Services CDNA →
CAI, Caris Life Sciences Inc.
We develop and commercialize innovative solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
Our entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets.
Our platform is purpose-built to leverage the convergence of next-generation sequencing ("NGS"), artificial intelligence ("AI") and machine learning ("ML") technologies, and high-performance computing.
The business
What it sells, where the money comes from, the kind of company it is.
The business in brief
read the 10-K →What this business is and what moves its needle, from its own SEC filings.
- Situation
- Distress / turnaround. Thin interest coverage, or operating cash burned against real debt, across the record. The balance sheet carries this situation; the debt schedule sets the clock.
- What moves the needle
- Operating margin has run around −62% through the cycle, the operating line deeply negative — so the lever is the path to a margin at all: revenue growth against the cost curve and the cash runway, not the level of a margin that isn't there yet. Read this kind of business on volume, payer mix and reimbursement. On its own account, the filing leans hardest on pricing power & competition, set against the numbers in what the filing emphasizes, below.
Every line is arithmetic on the company's filings, shown in full in the sections below.
The record
Ten years of arithmetic, read across the cycle.
The record, 2023–2025
realized figures from each filing · older years to the left| 2023’23 | 2024’24 | 2025’25 | TTMTTMMar 2026 | |
|---|---|---|---|---|
| Income statement | ||||
| $306M | $412M | $812M | $907M | RevenueRevenue |
| 49% | 41% | 28% | 26% | SG&A / revenueSG&A/rev |
| 38% | 28% | 13% | 12% | R&D / revenueR&D/rev |
| ($320M) | ($257M) | $45M | $108M | Operating incomeOp. inc. |
| −104.4% | −62.4% | 5.6% | 11.9% | Operating marginOp. mgn |
| ($341M) | ($282M) | ($68M) | $34M | Net incomeNet inc. |
| Cash flow & returns | ||||
| ($276M) | ($245M) | $83M | $147M | Operating cash flowOp. cash |
| $49M | $49M | $23M | $21M | DepreciationDeprec. |
| $1M | ($31M) | $59M | $22M | Working capital & otherWC & other |
| $22M | $8M | $16M | $24M | CapexCapex |
| 7.3% | 2.0% | 2.0% | 2.6% | Capex / revenueCapex/rev |
| ($298M) | ($254M) | $67M | $123M | Owner earningsOwner earn. |
| −97.5% | −61.5% | 8.2% | 13.6% | Owner earnings marginOE mgn |
| ($298M) | ($254M) | $67M | $123M | Free cash flowFCF |
| −97.5% | −61.5% | 8.2% | 13.6% | Free cash flow marginFCF mgn |
| $0 | $0 | $113K | — | BuybacksBuybacks |
| — | — | -12% | 6% | Return on equityROE |
| — | — | −12% | 6% | Retained to equityRetained/eq |
| Balance sheet | ||||
| — | $66M | $799M | $822M | Cash & investmentsCash+inv |
| — | $88M | $112M | $91M | ReceivablesReceiv. |
| — | $28M | $39M | $70M | Accounts payablePayables |
| — | $60M | $73M | $21M | Operating working capitalOper. WC |
| — | $216M | $998M | $1.0B | Current assetsCur. assets |
| — | $165M | $127M | $144M | Current liabilitiesCur. liab. |
| — | 1.3× | 7.8× | 7.0× | Current ratioCurr. ratio |
| — | $19M | $19M | $19M | GoodwillGoodwill |
| — | $344M | $1.1B | $1.2B | Total assetsAssets |
| — | $380M | $379M | $382M | Total debtDebt |
| — | $313M | ($420M) | ($441M) | Net debt / (cash)Net debt |
| -10.1× | -5.1× | 0.8× | 1.9× | Interest coverageInt. cov. |
| ($2.1B) | ($2.5B) | $577M | $593M | Shareholders’ equityEquity |
| 5.0% | 4.5% | 8.6% | 7.8% | Stock comp / revenueSBC/rev |
| Per share | ||||
| 34.9M | 35.5M | 167M | 283M | Shares out (diluted)Shares |
| $8.76 | $11.61 | $4.86 | $3.21 | Revenue / shareRev/sh |
| $-9.77 | $-7.94 | $-0.41 | $0.12 | EPS (diluted)EPS |
| $-8.54 | $-7.15 | $0.40 | $0.44 | Owner earnings / shareOE/sh |
| $-8.54 | $-7.15 | $0.40 | $0.44 | Free cash flow / shareFCF/sh |
| $0.64 | $0.24 | $0.10 | $0.08 | Cap. spending / shareCapex/sh |
| $-61.38 | $-70.40 | $3.45 | $2.10 | Book value / shareBVPS |
The diluted share count moved ×4.71 into 2025 — shares issued, not a split the totals corroborate — and the per-share figures carry the counts as filed.
The diluted share count moved ×1.69 into TTM — shares issued, not a split the totals corroborate — and the per-share figures carry the counts as filed.
The record, charted
FY2023–2025Each measure over its full record; the current point and the worst year marked.
Owner earnings vs. net income
Owner earningsNet incomeThe accountant's number, and the cash an owner can take; the gap is the tell.
Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.
In fiscal 2025 the business turned a $68M loss into $67M of owner earnings: more cash than the profit line showed, after the non-cash charges and the capital it put back in.
| FY2025 | FY2024 | FY2023 | |
|---|---|---|---|
| Reported net income | ($68M) | ($282M) | ($341M) |
| Depreciation & amortizationnon-cash charge added back | +$23M | +$49M | +$49M |
| Stock-based compensationreal costnon-cash, but a real cost | +$70M | +$19M | +$15M |
| Working capital & othertiming of cash in and out, other non-cash items | +$59M | −$31M | +$1M |
| Cash from operations | $83M | ($245M) | ($276M) |
| Capital expenditurecash put back in to keep running and to grow | −$16M | −$8M | −$22M |
| Owner earnings | $67M | ($254M) | ($298M) |
| Owner-earnings marginowner earnings ÷ revenue | 8% | -62% | -97% |
Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position . The cash-flow statement also adds stock comp back as non-cash, but it is a real cost paid in shares; counted as the expense it is (less $70M), owner earnings is nearer ($3M).
Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.
Quality & stewardship
Returns, the balance sheet, capital allocation, and pay.
Owner’s Scorecard
“We have identified a material weakness in our internal control over financial reporting.”
The figures below are only as sound as the controls that produced them. read the note →
Will it survive?
- Does not cover its interestOperating income $45M ÷ interest expense $57M
What this means
A full year of operating profit didn't cover the interest bill. This is the zombie zone: the business depends on refinancing, asset sales, or forbearance to service its debt.
- Net cashCash $796M + ST investments $2M − debt $379M
What this means
Cash and short-term investments exceed every dollar of debt by $420M, on net the company owes nothing, and can act from strength when others can't. Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.
- Not enough data
What this means
The filing data didn't include the inputs for this check.
Is it a good business?
- Not enough dataIndustry peers: median 1%
What this means
The filing data didn't include the inputs for this check.
- Positive this year, negative across the cyclelatest $67M = operating cash $83M − maintenance capex $16M (positive this year), after an earlier loss stretch (3-yr median -62%)Industry peers: median 5%
What this means
What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's 8% of revenue this year, a -62% median across 3 years. Treating stock comp as the real expense it is (less $70M of SBC) leaves ($3M).
- Loss, but cash-generativeNet income ($68M) · cash from operations $83M
In the filing’s words The filing discloses a material weakness in its financial controls — the reported numbers here, and the record built on them, are only as reliable as the controls that produced them.
What this means
The company reported a net loss, so a conversion ratio isn't meaningful. What matters then is whether operations still threw off cash, here, they did.
How is the cash used?
- Reinvests most of itDividends + buybacks $113K ÷ Owner Earnings $67M
What this means
Of $67M Owner Earnings, $113K (0%) went back to shareholders, $0 dividends, $113K buybacks. But the buybacks barely exceed stock issued to employees ($70M SBC), net of dilution, little was truly returned. Returning most of it is the mark of a mature business with little left to reinvest at a high return; reinvesting most could mean a long runway, or empire-building. The split doesn't say which; the return earned on it (see ROIC) does.
- Investing or harvesting? 0.72×HarvestingCapex $16M ÷ depreciation $23M
What this means
Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.
Graham’s defensive tests · 2 of 3 met
Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.
- Adequate size MissRevenue ≥ $2B · $812M
What this means
Big enough to weather a storm. Graham's 1972 floor was ~$100M of sales (≈ $700M today); we use a $2B revenue line as a conservative modern stand-in.
- Strong liquidity PassCurrent ratio ≥ 2× · 7.85×
What this means
Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.
- Conservative debt PassDebt ≤ working capital · $379M vs $871M WC
What this means
Graham's rule that borrowings not exceed net current assets. Capital-heavy and buyback-heavy firms routinely fail it, read it next to interest coverage, not alone.
- Moderate price —P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
What this means
Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are $-0.82/share (latest year $-0.24), the averaged base the calculator's gate runs on, and book value is $2.04/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.
Does AI threaten the moat?
Moderate contestabilityAI is likely to reshape costs and some products here without clearly contesting or sparing the core moat; how the company itself frames it is the tell.
Its FY2025 10-K names artificial intelligence as a competitive threat.
“Our competitors include numerous companies offering or seeking to offer tissue-based molecular profiling, blood-based early detection, blood-based therapy selection, MRD tracking, treatment monitoring, biopharma services, and genomic data and AI services.”
The question is whether a moat the record shows as durable outlasts a technology that lowers the cost of part of what the firm sells. The durability is read in the record above, the filing's own framing of AI beside it; the industry label decides nothing on its own.
Read from the filing's own risk factors, paired with the industry's structure under its SIC code; the durability is read above, the price below.
All figures as filed; the source filing is linked above.
Current Position
as of the latest quarter, Mar 31, 2026Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.
- Cash & short-term investments$822M
- Receivables$91M
- Other current assets$101M
- Debt due within a year$173K
- Accounts payable$70M
- Other current liabilities$74M
From the company's latest filing.
Management, ownership & pay
read the proxy →From the proxy: how much of the business the people running it own, and how they are paid.
- Insider ownership50%
The stake all directors and executive officers hold together, per the 2026 proxy: skin in the game, the first thing Munger reads.
- Stock-based compensation$70M
The slice of the business handed to employees in shares this year, 9% of revenue, equal to 155% of operating profit. Buffett's oldest accounting fight: this is compensation, compensation is an expense, real whether or not the headline earnings admit it. One trap: the cash-flow statement adds SBC back, so the operating cash, and the owner earnings drawn from it, are flattered by exactly this amount; counted as the cost it is, what an owner keeps is lower.
What an owner would ask, FY2025
read the 10-K →- Which reported numbers are a judgment call?Management names Revenue recognition, Stock compensation as critical estimates
each rests partly on management's judgment; the filing's note sets out the assumptionsverify →
The questions the record and the charts do not answer on their own; each carries the figure and the place to look.
Peers, Life Sciences Tools & Services
The same industry, side by side on owner economics. Each figure is a through-cycle median, so a peak or trough year can’t distort it; the group median at the foot is the line to read each against.
| Company | Revenue | Gross margin | Op. margin | ROIC | Owner earn. margin |
|---|---|---|---|---|---|
| FTREFortrea Holdings Inc. | $2.7B | — | 1.1% | 1% | 5% |
| PGNYProgyny | $1.3B | 21% | 4.2% | 13% | 10% |
| PNTGThe Pennant Group Inc. Common Stock | $948M | — | 4.8% | 9% | 5% |
| CAICaris Life Sciences Inc. | $812M | — | -62.4% | — | -62% |
| USPHU.S. Physical Therapy | $781M | — | 12.8% | 14% | 12% |
| TOIThe Oncology Institute Inc. | $503M | — | -18.9% | -55% | -10% |
| FLGTFulgent Genetics Inc. | $323M | 57% | -10.0% | -3% | 7% |
| GRALGRAIL Inc. Common Stock | $147M | — | -1627.6% | -19% | -464% |
| Group median | — | — | -4.4% | — | 5% |
The price
What a price has to assume.
What the price implies
reverse-DCFType today's close and see the owner-earnings growth you'd have to believe to justify it, beside what Caris Life Sciences Inc. has delivered.
—
9.0% = the 4.55% 10-year Treasury (Jul 15, 2026) + 4.45 points of equity premium. The rate you require is yours to set.
Enter a price above to run it.
A dated snapshot of the price you typed, the assumptions you set, and what the page showed for them. A snapshot is never edited after it is saved. Your notebook is yours alone — the commitment states what is stored and what we will never do.
Graham capped the multiple at 15×; Buffett and Munger let that rule go: a wonderful business can deserve 50× if the thesis holds. The gate marks the bargain-hunter's floor.
Prefilled with the 10-year Treasury (4.55%, as of Jul 15, 2026). Edit it for today’s exact figure, or a AAA corporate yield.
Graham measured a stock against the bond you could own instead, the heart of his margin of safety. Enter a price above to weigh the owner-earnings yield against this bond.
Free cash flow $123M on 283M shares outstanding, per the 10-Q cover, as of 2026-05-05; net cash $441M. The base is the latest year by default; Normalize values it on the through-cycle median owner-earnings margin (to avoid paying on a peak year). Net of stock comp treats option pay as the expense it is. Capex ($24M) runs well above depreciation ($21M), so this is a build-out; Steady-state swaps total capex for maintenance (≈ depreciation), lifting the base to about $131M, the cash it would throw off if it stopped expanding. The dials set the multiple a growth belief justifies; the price, and every dollar on this page, is yours.
Manual order: ← CAH its page in the Manual CAKE →
Industry order: ← BRKRP the Life Sciences Tools & Services chapter CDNA →